Stem Cell Therapy – StemCell Therapy

Page 55«..10 20..545556 57..60 70..»

Archive for the ‘Stem Cell Therapy’ Category

Merksamer Makes Only Bid For Stem Cell Agency Lobbying Contract

♫ Sunday, June 16th, 2013

Only one of California's lobbying firms
is interested in working for the California stem cell agency – at
least interested enough to put in a bid.

However, that is likely more of a
function of the small size of the contract – $65,000 – and the
entrenched nature of CIRM's existing lobbyist – Nielsen, Merksamer,
Parrinello, Gross & Leoni LLP – one of the state Capitol's
larger lobbying firms with $5 million in billings last year.

The firm touted its longstanding
connection to the $3 billion agency in its 21-page proposal in
response to a CIRM RFA this spring. The firm has been with CIRM since
2005.

Nielsen Merksamer's proposal also noted
a couple of other interesting aspects of the continuing arrangement.
CIRM will run out of money for new grants in 2017, and Nielsen
Merkasamer said,

“Furthermore, as a premier
legislative advocacy and (Nielsen's italics) ballot measure
law ?rm, Nielsen Merksamer can actively and effectively assist CIRM
as it contemplates returning to the voters for additional funding.”

The proposal also suggested that it can
conceal information that normally would be public record. The firm
said,

“Another unique advantage offered by
Nielsen Merksamer is that, unlike the vast majority of lobbying ?rms,
since we are a full-service law ?rm, our relationships with our
clients are subject to the attorney-client privilege.”

CIRM used such a technique in 2012 and 2008 in matters involving its budget and PR advice.

Nielsen Merksamer also said,

“(N)o one understands CIRM’s 'total
picture' better than Nielsen Merksamer. Not only has Nielsen
Merksamer been representing CIRM before the Legislature for the past
decade, but Nielsen Merksamer was also one of the principal drafters
of the aforementioned Proposition 71—which brought CIRM to life.
The depth of Nielsen Merksamer’s familiarity with, and
understanding of, CIRM’s mission and structure, the challenges it
faces, and the promise it holds simply cannot be matched by any other
legislative advocate.”

The firm said it would not need the
$65,000 offered by CIRM but would charge only $49,200 annually, about the same as
it has been paid for several years. Steve Merksamer and Gene Erbin,
who drafted portions of Proposition 71, would handle most of CIRM's
affairs. John Moffatt and Missy Johnson would also be available.

The firm's proposal outlined several
instances where it successfully killed legislation opposed by CIRM.
You can read about them in their proposal below.

Merskamer 2013
Lobbying Proposal by DavidJensen

Source:
http://feedproxy.google.com/~r/blogspot/uqpFc/~3/kTRN6kUuSDk/merksamer-makes-only-bid-for-stem-cell.html

♫ Posted in Stem Cell Therapy, Stem Cells | | Comments Off»

Compensation for Human Eggs Approved by Key California Senate Committee, But Not For CIRM Researchers

♫ Sunday, June 16th, 2013

Legislation that would permit women in
California to be paid for their eggs for scientific research
yesterday cleared a key state Senate committee and is likely headed
for the governor's desk.

The measure by Assemblywoman Susan
Bonilla, D-Concord, was approved on a 6-1 vote by the Senate Health
Committee and now goes to the Senate floor. Earlier, it passed the
Assembly on a 54-20 vote.

Some stem cell researchers and other
scientists have chafed under state restrictions that bar compensation
for eggs while that the same time fertility clinics are paying an average of $9,000 a session for eggs, with some prices going as high as $50,000.

However, the legislation will not
affect researchers using grants from the $3 billion California stem
cell agency. The agency's regulations bar compensation for eggs in
the research that it funds. That means that at least a two-tiered
research system would exist in California not to mention another tier
created by federal regulations that differ from both those of the
stem cell agency and those set by the legislation.

CIRM's restrictions are required by
Proposition 71, which created the agency in 2004, and cannot be
changed without a 70 percent vote of the legislature. Bonilla's bill
requires only a majority vote.

Bonilla's legislation is sponsored by
American Society for Reproductive Medicine, the chief industry
group for the largely unregulated fertility industry.

The analysis prepared for yesterday's
committee session summarized Bonilla's arguments for the measure in
this fashion:

“This bill seeks to create equity in
the field of medical research compensation by removing the
prohibition on compensation for women participating in oocyte (egg)
donation for medical research. All other research subjects are
compensated for their time, trouble, and inconvenience involved in
participating in research. AB 926 ensures that women are treated
equally to all other research subjects - allowing them to actively
evaluate their participation in research studies. Unfortunately, the
ban on compensation has had serious unintended consequences. It has
led to a de facto prohibition on women’s reproductive research in
California, adversely impacting the same women that the ban intended
to protect. With few oocytes donated, fertility research and
fertility preservation research has been at a standstill. This
greatly affects women suffering from fertility issues and women
facing cancer who would like to preserve their oocytes.”

A number of organizations are opposed
to the bill including the Center for Genetics and Society in Berkeley
and the Catholic Church. The bill analysis summarized some of the
opposition arguments in this fashion:

“Egg harvesting exposes healthy young
women to multiple synthetic hormones in order to produce many times
the normal number of eggs per cycle. One of the potential harms is
OHSS, which has resulted in hospitalizations and at least a few
documented deaths. These groups state that many experts remain
concerned about the long-term risks of these drugs, especially
their potential impact on infertility and various cancers.
Follow-up research on egg providers, which could establish the
frequency and severity of these adverse outcomes, is widely
recognized to be grossly inadequate.”

In addition to risk and religious
objections, opponents also argue that poor and minority women are
likely to be exploited by enterprises seeking their eggs to resell at
a profit.

No major stem cell research
organizations, including the California stem cell agency, have taken
a position on the bill. The legislation has received little public
attention, although The Sacramento Bee carried an article last March.
Ruha Benjamin, author of "People's Science" and assistant professor at Boston
University, also wrote about the measure in April on the Huffington
Post. Benjamin said,

“UC Berkeley professor Charis
Thompson compares egg
donation to 'other kinds of physically demanding service work,'
arguing for a 'salary negotiation between the state agency (or
relevant employer) and the donor.' This, she contends, is a 'sensible
and dignified recognition of [the donor's] work, time, and effort.'
And instead of refusing compensation to women, Thompson suggests that
we 'direct our efforts to understanding and minimizing' the risks.

“Indeed. Now more than ever, we must
redouble our efforts, because the market in eggs appears to be
expanding from private reproduction to public research, and
increasingly overseas, if the surrogacy
industry is any indication of how 'cheaper' women become a
reserve army of bio-labor in less regulated regions.”

Source:
http://feedproxy.google.com/~r/blogspot/uqpFc/~3/SVuriAz87l0/compensation-for-human-eggs-approved-by.html

♫ Posted in Stem Cell Therapy, Stem Cells | | Comments Off»

Cellular Dynamics: California Stem Cell Agency Recipient Plans $57 Million IPO

♫ Sunday, June 9th, 2013

A Wisconsin firm that is the
beneficiary of more than $16 million from the California stem cell
agency today announced that it intends to go public to raise $57.3
million for its iPS cell ventures.

Jamie Thomson
UCSB photo

The firm is Cellular Dynamics
International, Inc., and was co-founded by internationally known stem
cell scientist Jamie Thomson of the University of Wisconsin, who is
currently the company's chief scientific officer. Thomson is also a professor
at UC Santa Barbara, where he is co-director of the Center for Stem
Cell Biology and Engineering.

In March, the California stem cell
agency awarded a $16 million grant to Cellular Dynamics to derive
three iPS cell lines from 3,000 individuals as part of the agency's
stem cell banking initiative. (Here is a link to the grant review summary.)

The company said in its SEC
filings that it also will be the prime subcontractor on a $10 million
grant that the Coriell Institute for Medical Research of Camden,
N.J., received in the agency's stem cell banking round. Cellular Dynamics said
some of the funds from the IPO will be used to complete its
California laboratory in leased space at the Buck Institute in
Novato, north of San Francisco.

Cellular Dynamics was founded in 2004
and sold its first commercial product in 2010. It reported revenues
of $6.6 million in 2012 and losses of $22.3 million. It has 115
full-time and part-time employees worldwide.

The company said,

“During 2011 and 2012, we had three
large biopharmaceutical customers that individually accounted for
greater than 10% of our total revenue in one or both years. Eli Lilly
and Company (Lilly) accounted for 10% of total revenue in 2011 and
18% of total revenue in 2012. Hoffmann-La Roche Inc. (Roche)
accounted for 13% of total revenue in 2011 and GlaxoSmithKline plc
(GSK) accounted for 11% of our total revenue in 2012.”

Cellular Dynamics also said in its
filings,

“Our total revenue grew from $2.6
million in 2011 to $6.6 million in 2012, an increase of 154%. This
growth was driven by a 247% increase in sales of our iCell products
which grew from $1.5 million in 2011 to $5.2 million in 2012. At
December 31, 2011, our backlog of revenue expected to be recognized
in 2012 was $1.1 million. At December 31, 2012, our backlog of
revenue expected to be recognized in 2013 had grown to $4.1 million.

“For the three months ended March 31,
2013 our total revenue was $2.4 million, an increase of 109% over the
corresponding period in 2012. This growth was driven primarily by an
increase in iCell product sales, which grew from $0.6 million for the
three months ended March 31, 2012 to $1.8 million for the three
months ended March 31, 2013, an increase of 173%.”

Paul Knoepfler of UC Davis, writing on his blog, touched on some of the aspects of the IP issues involving
Cellular Dynamics and Japanese researcher Shinya Yamanaka, who won the Nobel Prize last year for discovering how to reprogram adult stem cells into pluripotent cells (the iPS process).

Knoepfler wrote,

"A
recent question is the issue of who has the intellectual property
(IP) rights to iPS cell technology. People have told me in the
past that they wondered if Cellular Dynamics has unambiguous rights
to develop all of these iPS cell-based products."

Knoepfler also wrote,

“This (the IPO) looks to
be very interesting and could transform the field as it develops.”

News coverage today of the IPO filing
was light, but is more expected to surface tomorrow. Here is a link to the only story that had surfaced as of this writing.

No price or date has yet been set for
the offering.

Source:
http://feedproxy.google.com/~r/blogspot/uqpFc/~3/0oup8hU2FGE/cellular-dynamics-california-stem-cell.html

♫ Posted in Stem Cell Therapy | | Comments Off»

Light Coverage of Cellular Dynamics IPO But One Exec Says It’s Good for Stem Cell Biz

♫ Sunday, June 9th, 2013

A handful of media outlets today
carried stories about the public stock offering announced yesterday
by Cellular Dynamics International, Inc., a Wisconsin firm that will
benefit to the tune of $16 million-plus from the California stem cell agency.

Kathleen Gallagher of the Milwaukee
Journal Sentinel described the company, founded by stem cell pioneer
Jamie Thomson, as in the business of making “fully functioning human cells in industrial quantities.”

Judy Newman of the Wisconsin State
Journal in Madison, where the company is based, quoted Beth Donley,
chief executive of Stemina
Biomarker Discovery, as saying,

“It can’t help but increase the
value of other stem cell companies.”

Thomson is a professor both at the
University of Wisconsin in Madison and at UC Santa Barbara, and we
queried Dennis Clegg, co-director of the Center for Stem Cell
Biology and Engineering at UC Santa Barbara, about the school's
ties to Cellular Dynamics, which hopes to take in $57 million in its public offering.

He replied in an email that Santa
Barbara has a collaboration with Cellular Dynamics and the University
of Wisconsin to develop a vision-restoring, stem-cell-based therapy
for people with advanced retinal diseases. That $900,000 effort is financed by the Foundation Fighting Blindness.

The California stem cell agency grant
to Cellular Dynamics is for work at the stem cell bank being created
at the Buck Institute in Novato, north of San Francisco.

The Milwaukee Business Journal and
Genomeweb also carried stories on the IPO.

Source:
http://feedproxy.google.com/~r/blogspot/uqpFc/~3/iGlLbdQVr0Y/light-coverage-of-cellular-dynamics-ipo.html

♫ Posted in Stem Cell Therapy | | Comments Off»

Pomeroy on Doing the Right Thing and Foster Care

♫ Sunday, June 9th, 2013

Claire Pomeroy
CIRM photo

On Claire Pomeroy's last day as a
member of the governing board of the $3 billion California stem cell
agency, she also published an essay on the Huffington Post in which
she discussed fleeing from an abusive home at age 14.

Pomeroy, former vice chancellor and
dean of the medical school at UC Davis and now president of the Lasker Foundation in New York, wrote last month,

“For some children, the uncertainty
of life on the street is better than certainty of violence at home.
It was for me. At age 14, I escaped from an abusive home with no
money, nowhere to go and only the clothes I was wearing. I remember
staring into the night, standing somewhere between fear and freedom.
I became one of the millions of homeless teens, yet I was lucky
because foster care ultimately saved me.”
“However, after an emergency
placement and three foster homes, the challenges were not over. At 17
I aged out of the foster care system early when my foster parents
moved out of state. On my own again, I had to find a job, a place to
live and finish high school. Then I climbed the next mountain to
graduate from college and medical school.”

Pomeroy said she only recently began
publicly talking about her foster care experience. She said she is
doing so because “many people lack an understanding of
the harsh statistics and their impact on the country's future. The
nation faces a crisis that demands a call to action to start truly
caring about foster youth before it is too late.”

She said that she was “lucky” in the
foster care system but said that many children, particularly minorities among others such as the disabled, were not as fortunate and “were failed by the system and society.” Pomeroy called them
“throwaway children” who were “robbed of their ideals, gave up
hope and struggled to find a reason to live.”

Less than half of the foster children
who “age out” of the system graduate from high school, she wrote. Only 3
percent to 11 percent earn a bachelor's degree. More than
400,000 children were in foster care in 2011 and have a one in 11 chance
of being homeless.

Pomeroy called for expansion and
improvement of foster care across the country. “It is time to stop
forcing children to be the heroes of their own survival,” she
wrote. “Now is the time to do the right the right thing.”

------

On a personal note, we have four
grandchildren, one of whom was adopted out of foster care as a
toddler. The other was adopted at birth. Some of the siblings of
those two African-American children remain in foster care today.

Source:
http://feedproxy.google.com/~r/blogspot/uqpFc/~3/zancriHTUC4/pomeroy-on-doing-right-thing-and-foster.html

♫ Posted in Stem Cell Therapy | | Comments Off»

Cellular Dynamics: California Stem Cell Agency Recipient Plans $57 Million IPO

♫ Sunday, June 9th, 2013

A Wisconsin firm that is the
beneficiary of more than $16 million from the California stem cell
agency today announced that it intends to go public to raise $57.3
million for its iPS cell ventures.

Jamie Thomson
UCSB photo

The firm is Cellular Dynamics
International, Inc., and was co-founded by internationally known stem
cell scientist Jamie Thomson of the University of Wisconsin, who is
currently the company's chief scientific officer. Thomson is also a professor
at UC Santa Barbara, where he is co-director of the Center for Stem
Cell Biology and Engineering.

In March, the California stem cell
agency awarded a $16 million grant to Cellular Dynamics to derive
three iPS cell lines from 3,000 individuals as part of the agency's
stem cell banking initiative. (Here is a link to the grant review summary.)

The company said in its SEC
filings that it also will be the prime subcontractor on a $10 million
grant that the Coriell Institute for Medical Research of Camden,
N.J., received in the agency's stem cell banking round. Cellular Dynamics said
some of the funds from the IPO will be used to complete its
California laboratory in leased space at the Buck Institute in
Novato, north of San Francisco.

Cellular Dynamics was founded in 2004
and sold its first commercial product in 2010. It reported revenues
of $6.6 million in 2012 and losses of $22.3 million. It has 115
full-time and part-time employees worldwide.

The company said,

“During 2011 and 2012, we had three
large biopharmaceutical customers that individually accounted for
greater than 10% of our total revenue in one or both years. Eli Lilly
and Company (Lilly) accounted for 10% of total revenue in 2011 and
18% of total revenue in 2012. Hoffmann-La Roche Inc. (Roche)
accounted for 13% of total revenue in 2011 and GlaxoSmithKline plc
(GSK) accounted for 11% of our total revenue in 2012.”

Cellular Dynamics also said in its
filings,

“Our total revenue grew from $2.6
million in 2011 to $6.6 million in 2012, an increase of 154%. This
growth was driven by a 247% increase in sales of our iCell products
which grew from $1.5 million in 2011 to $5.2 million in 2012. At
December 31, 2011, our backlog of revenue expected to be recognized
in 2012 was $1.1 million. At December 31, 2012, our backlog of
revenue expected to be recognized in 2013 had grown to $4.1 million.

“For the three months ended March 31,
2013 our total revenue was $2.4 million, an increase of 109% over the
corresponding period in 2012. This growth was driven primarily by an
increase in iCell product sales, which grew from $0.6 million for the
three months ended March 31, 2012 to $1.8 million for the three
months ended March 31, 2013, an increase of 173%.”

Paul Knoepfler of UC Davis, writing on his blog, touched on some of the aspects of the IP issues involving
Cellular Dynamics and Japanese researcher Shinya Yamanaka, who won the Nobel Prize last year for discovering how to reprogram adult stem cells into pluripotent cells (the iPS process).

Knoepfler wrote,

"A
recent question is the issue of who has the intellectual property
(IP) rights to iPS cell technology. People have told me in the
past that they wondered if Cellular Dynamics has unambiguous rights
to develop all of these iPS cell-based products."

Knoepfler also wrote,

“This (the IPO) looks to
be very interesting and could transform the field as it develops.”

News coverage today of the IPO filing
was light, but is more expected to surface tomorrow. Here is a link to the only story that had surfaced as of this writing.

No price or date has yet been set for
the offering.

Source:
http://feedproxy.google.com/~r/blogspot/uqpFc/~3/0oup8hU2FGE/cellular-dynamics-california-stem-cell.html

♫ Posted in Stem Cell Therapy, Stem Cells | | Comments Off»

Light Coverage of Cellular Dynamics IPO But One Exec Says It’s Good for Stem Cell Biz

♫ Sunday, June 9th, 2013

A handful of media outlets today
carried stories about the public stock offering announced yesterday
by Cellular Dynamics International, Inc., a Wisconsin firm that will
benefit to the tune of $16 million-plus from the California stem cell agency.

Kathleen Gallagher of the Milwaukee
Journal Sentinel described the company, founded by stem cell pioneer
Jamie Thomson, as in the business of making “fully functioning human cells in industrial quantities.”

Judy Newman of the Wisconsin State
Journal in Madison, where the company is based, quoted Beth Donley,
chief executive of Stemina
Biomarker Discovery, as saying,

“It can’t help but increase the
value of other stem cell companies.”

Thomson is a professor both at the
University of Wisconsin in Madison and at UC Santa Barbara, and we
queried Dennis Clegg, co-director of the Center for Stem Cell
Biology and Engineering at UC Santa Barbara, about the school's
ties to Cellular Dynamics, which hopes to take in $57 million in its public offering.

He replied in an email that Santa
Barbara has a collaboration with Cellular Dynamics and the University
of Wisconsin to develop a vision-restoring, stem-cell-based therapy
for people with advanced retinal diseases. That $900,000 effort is financed by the Foundation Fighting Blindness.

The California stem cell agency grant
to Cellular Dynamics is for work at the stem cell bank being created
at the Buck Institute in Novato, north of San Francisco.

The Milwaukee Business Journal and
Genomeweb also carried stories on the IPO.

Source:
http://feedproxy.google.com/~r/blogspot/uqpFc/~3/iGlLbdQVr0Y/light-coverage-of-cellular-dynamics-ipo.html

♫ Posted in Stem Cell Therapy, Stem Cells | | Comments Off»

Pomeroy on Doing the Right Thing and Foster Care

♫ Sunday, June 9th, 2013

Claire Pomeroy
CIRM photo

On Claire Pomeroy's last day as a
member of the governing board of the $3 billion California stem cell
agency, she also published an essay on the Huffington Post in which
she discussed fleeing from an abusive home at age 14.

Pomeroy, former vice chancellor and
dean of the medical school at UC Davis and now president of the Lasker Foundation in New York, wrote last month,

“For some children, the uncertainty
of life on the street is better than certainty of violence at home.
It was for me. At age 14, I escaped from an abusive home with no
money, nowhere to go and only the clothes I was wearing. I remember
staring into the night, standing somewhere between fear and freedom.
I became one of the millions of homeless teens, yet I was lucky
because foster care ultimately saved me.”
“However, after an emergency
placement and three foster homes, the challenges were not over. At 17
I aged out of the foster care system early when my foster parents
moved out of state. On my own again, I had to find a job, a place to
live and finish high school. Then I climbed the next mountain to
graduate from college and medical school.”

Pomeroy said she only recently began
publicly talking about her foster care experience. She said she is
doing so because “many people lack an understanding of
the harsh statistics and their impact on the country's future. The
nation faces a crisis that demands a call to action to start truly
caring about foster youth before it is too late.”

She said that she was “lucky” in the
foster care system but said that many children, particularly minorities among others such as the disabled, were not as fortunate and “were failed by the system and society.” Pomeroy called them
“throwaway children” who were “robbed of their ideals, gave up
hope and struggled to find a reason to live.”

Less than half of the foster children
who “age out” of the system graduate from high school, she wrote. Only 3
percent to 11 percent earn a bachelor's degree. More than
400,000 children were in foster care in 2011 and have a one in 11 chance
of being homeless.

Pomeroy called for expansion and
improvement of foster care across the country. “It is time to stop
forcing children to be the heroes of their own survival,” she
wrote. “Now is the time to do the right the right thing.”

------

On a personal note, we have four
grandchildren, one of whom was adopted out of foster care as a
toddler. The other was adopted at birth. Some of the siblings of
those two African-American children remain in foster care today.

Source:
http://feedproxy.google.com/~r/blogspot/uqpFc/~3/zancriHTUC4/pomeroy-on-doing-right-thing-and-foster.html

♫ Posted in Stem Cell Therapy, Stem Cells | | Comments Off»

Sugar 1week post stem cell therapy – Video

♫ Saturday, June 8th, 2013

Sugar 1week post stem cell therapy

By: Tim O #39;Neill, DVM

The rest is here:
Sugar 1week post stem cell therapy - Video

♫ Posted in Stem Cell Therapy | | Comments Off»

Streak’s Before/After Stemlogix Stem Cell Therapy – Video

♫ Saturday, June 8th, 2013

Streak #39;s Before/After Stemlogix Stem Cell Therapy
Check out Streak #39;s amazing Post Stemlogix Stem Cell Therapy progression video from day 1 to day 37 ! The day of the stem cell therapy Streak could barely wal...

By: Stemlogix, LLC

Visit link:
Streak's Before/After Stemlogix Stem Cell Therapy - Video

♫ Posted in Stem Cell Therapy | | Comments Off»

Stem Cell Therapy- Victoria Hicks – Video

♫ Saturday, June 8th, 2013

Stem Cell Therapy- Victoria Hicks

By: Victoria Hicks

Read more:
Stem Cell Therapy- Victoria Hicks - Video

♫ Posted in Stem Cell Therapy | | Comments Off»

BBC iScience Stem Cell Therapy – Video

♫ Friday, June 7th, 2013

BBC iScience Stem Cell Therapy
A fun, engaging and relevant programme, inspiring the viewer to consider the science within and how scientific process can be used to test ideas and develop theories, rather than just looking...

By: Lammas Science

View original post here:
BBC iScience Stem Cell Therapy - Video

♫ Posted in Stem Cell Therapy | | Comments Off»

Mickey’s Before

♫ Monday, June 3rd, 2013

Mickey #39;s Before After Stemlogix Stem Cell Therapy
Mickey, a 13 year old German Shepherd torn both of his ACLs and suffered from severe arthritis. Mickey has been treated with Stemlogix Stem Cell Therapy Platelet Max Platelet Rich Plasma...

By: Stemlogix, LLC

More:
Mickey's Before

♫ Posted in Stem Cell Therapy | | Comments Off»

Stem Cell Therapy in Spinal Cord Injury – Video

♫ Monday, June 3rd, 2013

Stem Cell Therapy in Spinal Cord Injury

By: Knowlege21

See the original post:
Stem Cell Therapy in Spinal Cord Injury - Video

♫ Posted in Stem Cell Therapy | | Comments Off»

Fibroblast Growth Factor FGF Stem Cell Therapy – Video

♫ Monday, June 3rd, 2013

Fibroblast Growth Factor FGF Stem Cell Therapy
Fibroblast Growth Factor Heals Heart Tissue by Feeding Stem Cells present.

By: David Dolores

Go here to read the rest:
Fibroblast Growth Factor FGF Stem Cell Therapy - Video

♫ Posted in Stem Cell Therapy | | Comments Off»

Thumb Arthroscopy with Stem Cell Therapy – Video

♫ Monday, June 3rd, 2013

Thumb Arthroscopy with Stem Cell Therapy
Hand surgeon Dr. Michael Fitzmaurice details the thumb arthroscopy procedure that he pioneered, involving an endoscopic approach and stem cell therapy (PRP) ...

By: Michael Fitzmaurice

See the original post here:
Thumb Arthroscopy with Stem Cell Therapy - Video

♫ Posted in Stem Cell Therapy | | Comments Off»

Vatican Funding for California Stem Cell Agency?

♫ Sunday, June 2nd, 2013

So what's with the Vatican sending cash
to the California stem cell agency? One would imagine that is an
improbable event since the agency is involved in human embryonic stem
cell research, which is an anathema to the Roman Catholic church.

However, CIRM President Alan Trounson
earlier this week disclosed the payment in an interview with Patt
Morrison of the Los Angeles Times. He said,

“Last
year I was invited to the Vatican to
present a paper, but when I sent in a summary of what I was going to
say, they decided not to have it. They sent a check to the treasurer
of California and the treasurer rang us up and said, "What the
heck is this check from the Vatican for?" It was for the
inconvenience!”

We wanted to know a little more about
this so we queried the agency about the matter. Kevin McCormack, a
CIRM spokesman, said,

“The money was actually a wire
transfer from the Vatican to us for $453.23 and it went to CIRM's
account. It was to reimburse us for money spent on plane tickets,
etc., for Dr. Trounson to attend the Vatican conference on stem
cells.”

Source:
http://feedproxy.google.com/~r/blogspot/uqpFc/~3/bOQKBXJGmJ8/vatican-funding-for-california-stem.html

♫ Posted in Stem Cell Therapy | | Comments Off»

Bluebird bio of Massachusetts Still Waiting for California Stem Cell Money

♫ Sunday, June 2nd, 2013

Seven months after the California stem
cell agency awarded $9.4 million to bluebird bio of Cambridge, Mass.,
the company has yet to receive any of the cash from the Golden State.

Kevin McCormack, a spokesman for the $3
billion agency, this week said negotiations are still underway with
the bluebird, which is planning to go public, but did not elaborate. Post-award negotiations are
common at the agency, but generally take much less time.

The cash from CIRM is scheduled to
assist in clinical trials for a stem cell-gene therapy to correct a genetic disease in young patients with B-thalassemia, a
rare blood disorder that can cause widespread organ damage
and premature death.

Earlier this month, bluebird bio, which
prefers the lower case lettering for its name, announced that it
intends to take the company public in an $86 million offering. In
March, it announced a collaboration with Celgene that provided for an upfront payment of $75 million and promised up to $225 million per
product in potential option fees and clinical and regulatory
milestones. The CIRM grant is conditioned on a matching commitment
from bluebird.

Cash from the stem cell agency can only
be spent on operations within California. According to the CIRM summary of the review of the bluebird application, which was scored
at 73, the company said,

“We will have at least two clinical
sites in California, and more likely up to 4 sites, 2) our viral
vector manufacturing will occur in California, 3) our cell processing
will occur in California, 4) we will hire several consultants and
full-time employees within California to support the program.
Overall, several million dollars will be spent employing the services
of people, academic institutions, and other companies within the
state of California.”

The company has said that it is working
with Donald Kohn at UCLA and Elliot Vichinsky at Oakland's Children's
Hospital.

The bluebird web site lists a
California location for bluebird at 1001 Bayhill Dr, Suite 200, in
San Bruno, which is south of San Francisco. An Internet search
indicates that is a generic address for a number of business
including a realty firm, a roof repair business and a family law
attorney. The California Stem Cell Report has asked bluebird to
clarify the nature of the address.

In an interview last October with Ron Leuty of the
San Francisco Business Times, David Davidson, the lead scientist on
the project, said,

“We began the process (with CIRM)
early in (2012) but discussions have been going on for over a year
about potentially pursuing this.

“The interaction with CIRM has been
extraordinarily collaborative. We had contact with the coordinators
at CIRM that helped us manage the process. It took a lot of effort on
our part to put together a dossier providing support for our program.
It was really like a mini-regulatory filing — on the science, the
preclinical toxicology work that we’ve done, a detailed plan for
the trial, a detailed plan for the budgets, a detailed plan on how we
intended to spend the CIRM money in California. That was an important
part of it. They wanted a clear plan on how this investment would be
spent."

Source:
http://feedproxy.google.com/~r/blogspot/uqpFc/~3/zR-Ht90u_7o/bluebird-bio-of-massachusetts-still.html

♫ Posted in Stem Cell Therapy | | Comments Off»

$70 Million Alpha Stem Cell Clinic Proposal Draws Reader Comment

♫ Sunday, June 2nd, 2013

In addition to the comments filed online in connection with the $70 million proposal to create Alpha Clinics in California for stem cell treatments, two other readers commented privately in emails.

One came from a close observer of the
stem cell agency who said, “If done right -- and I'm sure you and I
agree that is a big 'if' – it could be an outstanding legacy.”

The other comment came from a
physician-researcher at a major California institution and was longer
and more critical. Here is the text.

“Another boondoggle for some medical
schools but made to order for private operators like for profit
cancer, dialysis, and laser eye specialty clinics that do one
procedure. I can see each of the medical schools gifted with
one as they each were gifted with about 25 million dollars for stem
cell institute buildings; and CIRM and (Irv) Weissman's companies
like Stem Cells, Inc., getting a piece of the action as well. Of
course the deans and chancellors on the CIRM steering committee will
vote for it. How can they not? It's money in their pockets.

“This has the fit and feel of, say,
old Latin American Laetrile clinics or offshore clinics offering
suspect surgeries or injections for cancers, Parkinson's disease, and
the like. It makes no difference that they are set up in
California. CIRM will pay for an unneeded infrastructure that
will be empty space and staff sitting on their hands 99% of the
time. Or worse yet, CIRM will pay but the space will be used
for other things, other clinic procedures paid for by insurance.

“Now (CIRM President Alan) Trounson and
CIRM want to get into the medical tourism business making California
a 'go-to place' for stem cell treatments. They want to start
with bone marrow injections and transplants, procedures that cancer
centers do regularly. All CIRM needs is a drug or treatment.
It's not like there are tons of drugs out there and the only barrier
is the lack of clinical space and capacity. The start up time
for any one drug is very long.

“NIH at various times has tried to
organize clinical trials groups with infrastructure, like quick
reaction forces, ready to gear up for a new trial at the drop of a
hat. They mainly did nothing but suck money, kept staff employed,
because there are generally few drugs ready for early human trials
and each treatment that is brought along requires a unique contract,
ethics reviews, and different facilities, equipment and staff than
planned for. The latest incarnation are CTSAs or CTSIs,
clinical and translational science centers funded by the federal NIH
that most if not all California medical schools already have.

“The CIRM clinics are going to be
generic stem cell clinics advancing California tourism. Come to
California, we will inject stem cells for any illness, in any part of
your body, never mind that cancer is different from heart disease is
different from bone disease is different from brain disease, no
matter. Next step is for CIRM to form a travel agency with
discounted air and Ritz Carlton packages for patients and extended
family non-stop from China. There is likely considerable
revenue to be generated here and Trounson, Weissman, and (Robert)
Klein (former CIRM chairman) should find a way to benefit. It sounds
so wonderful!! The public will love it. Now all they need
are some treatments. Love the name: Alpha Clinics, they
wouldn't want to start with Beta test clinics when they can go big
from the get-go. What an irresponsible waste.”

The other comments can be found at the end of the original item or in the column to the right of this item, headed "recent comments."

Source:
http://feedproxy.google.com/~r/blogspot/uqpFc/~3/nKbicxl9mzA/70-million-alpha-stem-cell-clinic.html

♫ Posted in Stem Cell Therapy | | Comments Off»

California’s Alpha Stem Cell Clinics: Open in 2014, Six to Eight Locations

♫ Sunday, June 2nd, 2013

The San Francisco Business Times
yesterday said that the first Alpha Clinic sponsored by the $3
billion California stem cell agency could open as early as 2014.

The timing was disclosed by CIRM
President Alan Trounson in an article by Ron Leuty, who also reported
that that Trounson's $70 million proposal (see here and here) would involve as many as
six to eight clinics. The locations of the clinics was not disclosed
and would be subject to a competitive RFA. However, Leuty's piece
mentioned UC San Francisco and Stanford.

The article also said initial
treatments might focus on eye disease, “brain therapies” and
spinal cord injuries.

The Alpha Clinic plan is scheduled to
come before the CIRM board in late July. The proposal is aimed at
speeding stem cell treatments and creating something of a one-stop
shopping experience for patients.

Once the CIRM board approves the
concept, an RFA will be issued and interested institutions will have
to submit bids and compete for funding.

Source:
http://feedproxy.google.com/~r/blogspot/uqpFc/~3/So_NOlmLU2E/californias-alpha-stem-cell-clinics.html

♫ Posted in Stem Cell Therapy | | Comments Off»

Page 55«..10 20..545556 57..60 70..»

2025 © StemCell Therapy is proudly powered by WordPress
Entries (RSS) Comments (RSS) | Violinesth by Patrick